Metformin Hydrochloride Aspire

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Aspire, is a biguanide presented as an oral formulation for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control elevated blood glucose levels.

GNH USA supplies Metformin Hydrochloride Aspire as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements.

Metformin Hydrochloride is used primarily in the management of disorders related to glucose metabolism and insulin resistance.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes through improved insulin sensitivity. - Polycystic ovary syndrome: reduces insulin resistance and may aid in restoring ovulatory function.

Metformin Hydrochloride is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: rare liver dysfunction. - Hypoglycaemia: uncommon when used alone, may occur with other antidiabetic agents. - Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption.

Metformin Hydrochloride requires careful assessment and monitoring to minimise risks.

- Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic impairment: use with caution in patients with liver disease due to lactic acidosis risk. - Alcohol consumption: limit intake as excessive alcohol increases lactic acidosis risk. - Pregnancy safety: classified Category B; benefits should outweigh potential risks. - Vitamin B12 monitoring: consider periodic assessment during prolonged therapy. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Metformin Hydrochloride may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol excess: potentiates lactic acidosis. - Carbamazepine: may reduce metformin effectiveness. - Nitrates: concurrent use may increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increased risk of hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics: can affect renal clearance of metformin.